Associations - CDK4 inhibitor

HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	palbociclib Sensitive: A1 - Approval ASCO 2023 - 1 week (New C3) palbociclib Sensitive : A1 ASCO 2023 - 1wk	palbociclib Sensitive: A1 - Approval ASCO 2023 - 1 week palbociclib Sensitive : A1 ASCO 2023 - 1 week - (New C3)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	ribociclib Sensitive: A1 - Approval ASCO 2023 - 1 week (New C3) ribociclib Sensitive : A1 ASCO 2023 - 1wk	ribociclib Sensitive: A1 - Approval ASCO 2023 - 1 week ribociclib Sensitive : A1 ASCO 2023 - 1 week - (New C3)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	abemaciclib Sensitive: A1 - Approval ASCO 2023 - 1 week (New B) abemaciclib Sensitive : A1 ASCO 2023 - 1wk	abemaciclib Sensitive: A1 - Approval ASCO 2023 - 1 week abemaciclib Sensitive : A1 ASCO 2023 - 1 week - (New B)
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	palbociclib Resistant: A2 - Guideline ASCO 2023 - 1 week (New C3) palbociclib Resistant : A2 ASCO 2023 - 1wk	palbociclib Resistant: A2 - Guideline ASCO 2023 - 1 week palbociclib Resistant : A2 ASCO 2023 - 1 week - (New C3)
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	palbociclib Sensitive: B - Late Trials ASCO 2023 - 1 week (New B) palbociclib Sensitive : B ASCO 2023 - 1wk	palbociclib Sensitive: B - Late Trials ASCO 2023 - 1 week palbociclib Sensitive : B ASCO 2023 - 1 week - (New B)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	G1T38 Sensitive: B - Late Trials ASCO 2023 - 1 week (New B) G1T38 Sensitive : B ASCO 2023 - 1wk	G1T38 Sensitive: B - Late Trials ASCO 2023 - 1 week G1T38 Sensitive : B ASCO 2023 - 1 week - (New B)
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	ribociclib Sensitive: B - Late Trials ASCO 2023 - 1 week (New C3) ribociclib Sensitive : B ASCO 2023 - 1wk	ribociclib Sensitive: B - Late Trials ASCO 2023 - 1 week ribociclib Sensitive : B ASCO 2023 - 1 week - (New C3)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	dalpiciclib Sensitive: B - Late Trials ASCO 2023 - 1 week (New C3) dalpiciclib Sensitive : B ASCO 2023 - 1wk	dalpiciclib Sensitive: B - Late Trials ASCO 2023 - 1 week dalpiciclib Sensitive : B ASCO 2023 - 1 week - (New C3)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	pyrotinib + dalpiciclib Sensitive: C2 – Inclusion Criteria ASCO 2023 - 1 week (New C3) pyrotinib + dalpiciclib Sensitive : C2 ASCO 2023 - 1wk	pyrotinib + dalpiciclib Sensitive: C2 – Inclusion Criteria ASCO 2023 - 1 week pyrotinib + dalpiciclib Sensitive : C2 ASCO 2023 - 1 week - (New C3)
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	abemaciclib Sensitive: C2 – Inclusion Criteria ASCO 2023 - 1 week (New C3) abemaciclib Sensitive : C2 ASCO 2023 - 1wk	abemaciclib Sensitive: C2 – Inclusion Criteria ASCO 2023 - 1 week abemaciclib Sensitive : C2 ASCO 2023 - 1 week - (New C3)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	BPI-16350 Sensitive: C2 – Inclusion Criteria ASCO 2023 - 1 week (New C3) BPI-16350 Sensitive : C2 ASCO 2023 - 1wk	BPI-16350 Sensitive: C2 – Inclusion Criteria ASCO 2023 - 1 week BPI-16350 Sensitive : C2 ASCO 2023 - 1 week - (New C3)
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	PF-07220060 Sensitive: C2 – Inclusion Criteria ASCO 2023 - 1 week (New C3) PF-07220060 Sensitive : C2 ASCO 2023 - 1wk	PF-07220060 Sensitive: C2 – Inclusion Criteria ASCO 2023 - 1 week PF-07220060 Sensitive : C2 ASCO 2023 - 1 week - (New C3)
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	pyrotinib + dalpiciclib Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) pyrotinib + dalpiciclib Sensitive : C3 ASCO 2023 - 1wk	pyrotinib + dalpiciclib Sensitive: C3 – Early Trials ASCO 2023 - 1 week pyrotinib + dalpiciclib Sensitive : C3 ASCO 2023 - 1 week - (New C3)
CDKN2A mutation	Squamous Cell Carcinoma of Head and Neck	CDKN2A mutation	Squamous Cell Carcinoma of Head and Neck	palbociclib Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) palbociclib Sensitive : C3 ASCO 2023 - 1wk	palbociclib Sensitive: C3 – Early Trials ASCO 2023 - 1 week palbociclib Sensitive : C3 ASCO 2023 - 1 week - (New C3)
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	ribociclib Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) ribociclib Sensitive : C3 ASCO 2023 - 1wk	ribociclib Sensitive: C3 – Early Trials ASCO 2023 - 1 week ribociclib Sensitive : C3 ASCO 2023 - 1 week - (New C3)
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	palbociclib Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) palbociclib Sensitive : C3 ASCO 2023 - 1wk	palbociclib Sensitive: C3 – Early Trials ASCO 2023 - 1 week palbociclib Sensitive : C3 ASCO 2023 - 1 week - (New C3)
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	abemaciclib Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) abemaciclib Sensitive : C3 ASCO 2023 - 1wk	abemaciclib Sensitive: C3 – Early Trials ASCO 2023 - 1 week abemaciclib Sensitive : C3 ASCO 2023 - 1 week - (New C3)
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	trastuzumab + palbociclib + pyrotinib Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) trastuzumab + palbociclib + pyrotinib Sensitive : C3 ASCO 2023 - 1wk	trastuzumab + palbociclib + pyrotinib Sensitive: C3 – Early Trials ASCO 2023 - 1 week trastuzumab + palbociclib + pyrotinib Sensitive : C3 ASCO 2023 - 1 week - (New C3)
PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	XZP 3287 Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) XZP 3287 Sensitive : C3 ASCO 2023 - 1wk	XZP 3287 Sensitive: C3 – Early Trials ASCO 2023 - 1 week XZP 3287 Sensitive : C3 ASCO 2023 - 1 week - (New C3)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	palbociclib + bosutinib Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) palbociclib + bosutinib Sensitive : C3 ASCO 2023 - 1wk	palbociclib + bosutinib Sensitive: C3 – Early Trials ASCO 2023 - 1 week palbociclib + bosutinib Sensitive : C3 ASCO 2023 - 1 week - (New C3)
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	abemaciclib + eFT226 Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) abemaciclib + eFT226 Sensitive : C3 ASCO 2023 - 1wk	abemaciclib + eFT226 Sensitive: C3 – Early Trials ASCO 2023 - 1 week abemaciclib + eFT226 Sensitive : C3 ASCO 2023 - 1 week - (New C3)
ESR1 mutation	Breast Cancer	ESR1 mutation	Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials ASCO 2023 - 1 week (New C3) CDK4 inhibitor + CDK6 inhibitor Resistant : C3 ASCO 2023 - 1wk	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials ASCO 2023 - 1 week CDK4 inhibitor + CDK6 inhibitor Resistant : C3 ASCO 2023 - 1 week - (New C3)
TP53 mutation	Breast Cancer	TP53 mutation	Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials ASCO 2023 - 1 week (New C3) CDK4 inhibitor + CDK6 inhibitor Resistant : C3 ASCO 2023 - 1wk	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials ASCO 2023 - 1 week CDK4 inhibitor + CDK6 inhibitor Resistant : C3 ASCO 2023 - 1 week - (New C3)
ER positive	HER2 Positive Breast Cancer	ER positive	HER2 Positive Breast Cancer	pyrotinib + dalpiciclib Sensitive: C3 – Early Trials ASCO 2023 - 1 week (New C3) pyrotinib + dalpiciclib Sensitive : C3 ASCO 2023 - 1wk	pyrotinib + dalpiciclib Sensitive: C3 – Early Trials ASCO 2023 - 1 week pyrotinib + dalpiciclib Sensitive : C3 ASCO 2023 - 1 week - (New C3)
HR positive + BRCA1 mutation + PALB2 mutation	HER2 Negative Breast Cancer	HR positive + BRCA1 mutation + PALB2 mutation	HER2 Negative Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials ASCO 2023 - 1 week (New C3) CDK4 inhibitor + CDK6 inhibitor Resistant : C3 ASCO 2023 - 1wk	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials ASCO 2023 - 1 week CDK4 inhibitor + CDK6 inhibitor Resistant : C3 ASCO 2023 - 1 week - (New C3)
HR positive + BRCA2 mutation + PALB2 mutation	HER2 Negative Breast Cancer	HR positive + BRCA2 mutation + PALB2 mutation	HER2 Negative Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials ASCO 2023 - 1 week (New C3) CDK4 inhibitor + CDK6 inhibitor Resistant : C3 ASCO 2023 - 1wk	CDK4 inhibitor + CDK6 inhibitor Resistant: C3 – Early Trials ASCO 2023 - 1 week CDK4 inhibitor + CDK6 inhibitor Resistant : C3 ASCO 2023 - 1 week - (New C3)
ER positive + CDK6 overexpression	HER2 Negative Breast Cancer	ER positive + CDK6 overexpression	HER2 Negative Breast Cancer	palbociclib Resistant: C3 – Early Trials ASCO 2023 - 1 week (New C3) palbociclib Resistant : C3 ASCO 2023 - 1wk	palbociclib Resistant: C3 – Early Trials ASCO 2023 - 1 week palbociclib Resistant : C3 ASCO 2023 - 1 week - (New C3)
TSC2 C1450G	HER2 Positive Breast Cancer	TSC2 C1450G	HER2 Positive Breast Cancer	palbociclib + lapatinib Sensitive: D – Preclinical NPJ Breast Cancer - 3 weeks (New D) palbociclib + lapatinib Sensitive : D NPJ Breast Cancer - 3wk	palbociclib + lapatinib Sensitive: D – Preclinical NPJ Breast Cancer - 3 weeks palbociclib + lapatinib Sensitive : D NPJ Breast Cancer - 3 weeks - (New D)
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	ribociclib Sensitive: A1 - Approval ribociclib Sensitive : A1	ribociclib Sensitive: A1 - Approval ribociclib Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + abemaciclib Sensitive: A2 - Guideline trastuzumab + abemaciclib Sensitive : A2	trastuzumab + abemaciclib Sensitive: A2 - Guideline trastuzumab + abemaciclib Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	ribociclib Sensitive: A2 - Guideline ribociclib Sensitive : A2	ribociclib Sensitive: A2 - Guideline ribociclib Sensitive : A2
No biomarker	Breast Cancer	No biomarker	Breast Cancer	abemaciclib Sensitive: A2 - Guideline abemaciclib Sensitive : A2	abemaciclib Sensitive: A2 - Guideline abemaciclib Sensitive : A2
No biomarker	Liposarcoma	No biomarker	Liposarcoma	palbociclib Sensitive: A2 - Guideline palbociclib Sensitive : A2	palbociclib Sensitive: A2 - Guideline palbociclib Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	palbociclib Sensitive: A2 - Guideline palbociclib Sensitive : A2	palbociclib Sensitive: A2 - Guideline palbociclib Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	abemaciclib Sensitive: A2 - Guideline abemaciclib Sensitive : A2	abemaciclib Sensitive: A2 - Guideline abemaciclib Sensitive : A2
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Sensitive: A2 - Guideline CDK4 inhibitor + CDK6 inhibitor Sensitive : A2	CDK4 inhibitor + CDK6 inhibitor Sensitive: A2 - Guideline CDK4 inhibitor + CDK6 inhibitor Sensitive : A2
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	CDK4 inhibitor + CDK6 inhibitor + Aromatase inhibitor Sensitive: A2 - Guideline CDK4 inhibitor + CDK6 inhibitor + Aromatase inhibitor Sensitive : A2	CDK4 inhibitor + CDK6 inhibitor + Aromatase inhibitor Sensitive: A2 - Guideline CDK4 inhibitor + CDK6 inhibitor + Aromatase inhibitor Sensitive : A2
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	trilaciclib Sensitive: B - Late Trials trilaciclib Sensitive : B	trilaciclib Sensitive: B - Late Trials trilaciclib Sensitive : B
CCNE1 overexpression	Hormone Receptor Positive Breast Cancer	CCNE1 overexpression	Hormone Receptor Positive Breast Cancer	palbociclib Resistant: B - Late Trials palbociclib Resistant : B	palbociclib Resistant: B - Late Trials palbociclib Resistant : B
ER mutation	Estrogen Receptor Positive Breast Cancer	ER mutation	Estrogen Receptor Positive Breast Cancer	palbociclib Sensitive: B - Late Trials palbociclib Sensitive : B	palbociclib Sensitive: B - Late Trials palbociclib Sensitive : B
ER mutation	Breast Cancer	ER mutation	Breast Cancer	palbociclib Resistant: B - Late Trials palbociclib Resistant : B	palbociclib Resistant: B - Late Trials palbociclib Resistant : B
PLK1 overexpression	Hormone Receptor Positive Breast Cancer	PLK1 overexpression	Hormone Receptor Positive Breast Cancer	palbociclib Resistant: B - Late Trials palbociclib Resistant : B	palbociclib Resistant: B - Late Trials palbociclib Resistant : B
ER positive + PGR negative + HER-2 negative	HER2 Negative Breast Cancer	ER positive + PGR negative + HER-2 negative	HER2 Negative Breast Cancer	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	abemaciclib Sensitive: B - Late Trials abemaciclib Sensitive : B	abemaciclib Sensitive: B - Late Trials abemaciclib Sensitive : B
KRAS G13C	Non Small Cell Lung Cancer	KRAS G13C	Non Small Cell Lung Cancer	abemaciclib Sensitive: B - Late Trials abemaciclib Sensitive : B	abemaciclib Sensitive: B - Late Trials abemaciclib Sensitive : B
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Sensitive: B - Late Trials CDK4 inhibitor + CDK6 inhibitor Sensitive : B	CDK4 inhibitor + CDK6 inhibitor Sensitive: B - Late Trials CDK4 inhibitor + CDK6 inhibitor Sensitive : B
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	abemaciclib Sensitive: B - Late Trials abemaciclib Sensitive : B	abemaciclib Sensitive: B - Late Trials abemaciclib Sensitive : B
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	palbociclib + abemaciclib Sensitive: B - Late Trials palbociclib + abemaciclib Sensitive : B	palbociclib + abemaciclib Sensitive: B - Late Trials palbociclib + abemaciclib Sensitive : B
HER-2 mutation	Breast Cancer	HER-2 mutation	Breast Cancer	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B
AKT1 mutation	Breast Cancer	AKT1 mutation	Breast Cancer	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B
BRCA1 mutation	Breast Cancer	BRCA1 mutation	Breast Cancer	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B
BRCA2 mutation	Breast Cancer	BRCA2 mutation	Breast Cancer	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B
ATM mutation	Breast Cancer	ATM mutation	Breast Cancer	ribociclib Resistant: B - Late Trials ribociclib Resistant : B	ribociclib Resistant: B - Late Trials ribociclib Resistant : B
CDKN2A mutation	Breast Cancer	CDKN2A mutation	Breast Cancer	ribociclib Resistant: B - Late Trials ribociclib Resistant : B	ribociclib Resistant: B - Late Trials ribociclib Resistant : B
FRS2 mutation	Breast Cancer	FRS2 mutation	Breast Cancer	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B
MDM2 mutation	Breast Cancer	MDM2 mutation	Breast Cancer	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B
PRKCA mutation	Breast Cancer	PRKCA mutation	Breast Cancer	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B
CHD4 mutation	Breast Cancer	CHD4 mutation	Breast Cancer	ribociclib Resistant: B - Late Trials ribociclib Resistant : B	ribociclib Resistant: B - Late Trials ribociclib Resistant : B
BCL11B mutation	Breast Cancer	BCL11B mutation	Breast Cancer	ribociclib Resistant: B - Late Trials ribociclib Resistant : B	ribociclib Resistant: B - Late Trials ribociclib Resistant : B
CDKN2B mutation	Breast Cancer	CDKN2B mutation	Breast Cancer	ribociclib Resistant: B - Late Trials ribociclib Resistant : B	ribociclib Resistant: B - Late Trials ribociclib Resistant : B

CDK4 inhibitor

CDK4 inhibitor

Associations(403)

Associations
(403)